Selective killing of cancer cells by small molecules targeting heat shock stress response
1Department of Biology, Alpine Therapeutics, Inc., 13350 Camino Del Sur, No. 8, San Diego, CA 92129, USA.
Abstract:
HSF1 heat shock response has emerged as a valuable non-oncogenetic intervention point in targeted cancer therapy. Current reporter based high throughput screening has led to the discovery of several compounds or chemotypes that are effective in the growth inhibition of multiple cancer cell lines and relevant animal tumor models. However, some intrinsic limitations of reporter based assays can potentially lead to biased results. Using a previously validated high content image based assay, we performed a phenotypic screen targeting HSF1 heat shock pathway with a chemically diversified library of over 100,000 compounds. Several novel functional inhibitors of HSF1 pathway were identified with different chemotypes. Western blot analysis confirmed that selective compounds inhibit phosphorylation of HSF1, followed by reduced expression of HSP proteins. Moreover, HeLa cells stably transfected with HSF1 shRNA were more resistant to the compound treatment under lethal temperature than cells containing HSF1, validating HSF1 dependent mechanism of action. These compounds demonstrate nanomolar potency toward multiple cancer cell lines with relatively low cytotoxicity to normal cells. Further SAR and target identification study will pave the way for the potential development of next generation anticancer drugs.
Insights
Researchers identified novel compounds targeting the heat shock factor 1 (HSF1) pathway for cancer therapy. These inhibitors show potent cancer cell growth inhibition with low normal cell toxicity, offering a promising new avenue for drug development.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Heat shock response mediated by heat shock factor 1 (HSF1) is a potential non-oncogenetic target in cancer therapy.
- Reporter-based high-throughput screening has identified HSF1 inhibitors, but limitations may cause biased results.
Purpose of the Study:
- To identify novel HSF1 pathway inhibitors using a high-content image-based phenotypic screen.
- To validate the mechanism of action and therapeutic potential of identified compounds.
Main Methods:
- Phenotypic screening of over 100,000 compounds using a validated high-content image-based assay targeting the HSF1 pathway.
- Western blot analysis to confirm HSF1 phosphorylation inhibition and HSP protein reduction.
- Validation of HSF1-dependent mechanism using HSF1 shRNA in HeLa cells.
Main Results:
- Identification of novel chemotypes functionally inhibiting the HSF1 pathway.
- Selective compounds demonstrated nanomolar potency against multiple cancer cell lines.
- Compounds exhibited low cytotoxicity to normal cells, with HSF1 knockdown conferring resistance.
Conclusions:
- The study identified potent and selective HSF1 pathway inhibitors with potential as next-generation anticancer drugs.
- The validated HSF1-dependent mechanism supports further development for targeted cancer therapy.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The Intrinsic Apoptotic Pathway
Treatment Resistant Cancers
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...


